斯佩罗治疗公司（Spero Therapeutics Inc.）与信达生物（Innovent Biologics）宣布，双方将合作推进一项针对干燥综合征的创新疗法临床研究。根据最新规划，该疗法的二期临床试验预计于2027年初在中国正式启动。
干燥综合征是一种慢性自身免疫性疾病，主要影响唾液腺和泪腺，导致患者出现口干、眼干等症状，目前在中国乃至全球范围内均缺乏高效的治疗方案。此次启动的二期试验旨在评估候选药物的安全性与有效性，为后续的临床开发奠定关键基础。
此次合作结合了斯佩罗治疗公司在感染性疾病与炎症领域的技术积累，以及信达生物在中国市场的临床开发与商业化优势。若试验进展顺利，该药物有望为中国的干燥综合征患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.